Listed

Co-Diagnostics, Inc.: Form 10-K for the period ended Dec 31, 2019

Filed with the SEC on Mar 30, 2020 and accepted by EDGAR at Mar 30, 2020, 17:30 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2019-12-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue12 months2019-01-01 to 2019-12-31$215.0kus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Cost of revenue12 months2019-01-01 to 2019-12-31$112.4kus-gaap:CostOfRevenue
Gross profit12 months2019-01-01 to 2019-12-31$102.5kus-gaap:GrossProfit
Research and development12 months2019-01-01 to 2019-12-31$1.4mus-gaap:ResearchAndDevelopmentExpense
Operating income12 months2019-01-01 to 2019-12-31−$5.9mus-gaap:OperatingIncomeLoss
Net income12 months2019-01-01 to 2019-12-31−$6.2mus-gaap:NetIncomeLoss
Operating cash flow12 months2019-01-01 to 2019-12-31−$5.5mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure12 months2019-01-01 to 2019-12-31$113.2kus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2019-12-31$893.1kus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2019-12-31$1.6mus-gaap:AssetsCurrent
Total assetsAt period end2019-12-31$2.2mus-gaap:Assets
Current liabilitiesAt period end2019-12-31$328.1kus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2019-12-31$478.1kus-gaap:Liabilities
Shareholders' equityAt period end2019-12-31$1.7mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001493152-20-005305. Last ingested by Listed: Oct 26, 2026, 16:01 ET. Listed shows no prices and gives no investment advice.